Bardoxolone methyl is an Antioxidant Inflammation Modulator (AIM) that activates Nrf2, thereby inducing the transcription of over 250 genes that decrease the level of oxidative stress and suppress several inflammatory mediators. In two Phase 2a studies, bardoxolone methyl was shown to produce a statistically significant increase in estimated glomerular filtration rate (eGFR) as well as improvements in other key markers of renal function in Stage 3b and 4 CKD patients with type 2 diabetes.

Chronic kidney disease (CKD) is a progressive loss of kidney function over a period of months or years, which can be caused by a number of conditions, including diabetes and high blood pressure. As kidney disease gets worse, wastes can build to high levels in the blood and patients may develop complications like high blood pressure, anemia (low blood count), weak bones, poor nutritional health and nerve damage. CKD also increases the risk of having heart and blood vessel disease. Early detection and treatment can often keep chronic kidney disease from getting worse. As kidney disease progresses, it may eventually lead to kidney failure, requiring dialysis or a kidney transplant.

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. Reata is the leader in discovering and developing novel anti-inflammatory drugs targeting Nrf2, which controls the body's production of antioxidant and detoxification enzymes and has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress. Reata is developing a portfolio of AIMs for a variety of inflammation-related diseases. The company's most advanced program is in late-stage clinical development for the treatment of CKD, a progressive condition affecting more than 26 million Americans. For more information, visit www.reatapharma.com.